News Agency
The Times

Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

  • Written by PR Newswire

BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and...

Read more: Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion